DIA: Driving Insights to Action
Science:Life Sciences
FDA has approved 11 biosimilars, but 41 biosimilars have been approved for use in Europe. The DIA 2018 Global Annual Meeting session “Interchangeable Biosimilars: A Global Perspective” explored the circumstances behind this difference and ways and reasons to close this gap, led by Session Chair Nielsen Hobbs (Executive Editor, US Policy & Regulatory, The Pink Sheet/Scrip), who was interviewed by DIA Senior Digital Copy Editor Chris Slawecki for this podcast. Watch the video of this podcast interview.
More Episodes
DIA/Tufts CSDD Research: AI Saving Time in Drug Development
2025-01-17
382
2025-01-17
382
DIA: Your Partner in Life Sciences Training and Development
2024-11-06
295
2024-11-06
295
GPP Experts Explain Authorship Algorithm
2024-04-23
274
2024-04-23
274
"Dossier in the Cloud" Democratizing Global Access
2024-04-02
314
2024-04-02
314
DIA: A Place Where You Can Make a Difference
2024-03-28
255
2024-03-28
255
Retiring TGA Head Maps Australia’s Post-Pandemic Future
2023-07-17
395
2023-07-17
395
Patient Engagement: Evolution of Who Knows What, Part 2
2023-06-14
287
2023-06-14
287
Patient Engagement: Evolution of Who Knows What, Part 1
2023-06-12
430
2023-06-12
430
Rwanda Welcomes African Medicines Agency Home
2022-11-30
603
2022-11-30
603
Will Technology Solve the Research “People Problem”?
2022-11-22
376
2022-11-22
376
Why Trans/Nonbinary Research Benefits All Communities
2022-11-18
520
2022-11-18
520
Digital Revolutionizing Data-Driven Reimbursement
2022-10-20
402
2022-10-20
402
China Sets New Record for Local Drug Approvals in 2021
2022-09-15
435
2022-09-15
435
WHO Pilot Formalizes CSA Process to Assist Developers
2022-08-02
428
2022-08-02
428
Get this podcast on your
phone, FREE
